靶向PSMA诊疗一体化:应用与进展  

Theranostics of targeted PSMA:application and progress

作　　者：张召奇[1] 赵新明[1] ZHANG Zhaoqi;ZHAO Xinming(Department of Nuclear Medicine,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,Hebei Province,China)

机构地区：[1]河北医科大学第四医院核医学科,河北石家庄050011

出　　处：《肿瘤影像学》2024年第5期475-484,共10页Oncoradiology

摘　　要：前列腺特异性膜抗原(prostate-specific membrane antigen,PSMA)最早在前列腺癌细胞中发现,是前列腺癌等高表达PSMA肿瘤诊疗的重要靶点。多种显像和治疗核素标记的PSMA不同配体在前列腺癌诊疗一体化中显示出重要作用。本文就靶向PSMA诊疗一体化的相关研究和临床应用进展进行述评。Prostate specific membrane antigen(PSMA)was first discovered in prostate cancer cells and is an important target for the diagnosis and treatment of tumors with high expression of PSMA such as prostate cancer.The development and application of a variety of imaging and therapeutic radionuclide-labeled targeted PSMA ligands play an important role in the theranostics of prostate cancer.This article reviewed the relevant research and clinical applications theranostics of PSMA.

关 键 词：前列腺癌 前列腺特异性膜抗原 抗体 小分子抑制剂 正电子发射体层成像 单光子发射体层成像 

分 类 号：R737.25[医药卫生—肿瘤] R445.6[医药卫生—临床医学]